Vanda Pharma & AnaptysBio Partner to Advance Imsidolimab for GPP Treatment

Vanda Pharmaceuticals Inc. and AnaptysBio, Inc. announced an exclusive worldwide licensing agreement for the development and marketing of imsidolimab (IL-36R antagonist mAb), which has successfully finished two registration-supporting global Phase...

Inhalon Biopharma Completes IND-Enabling Studies for RSV Therapy IN-002

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage firm developing a pioneering inhaled antibody platform for addressing acute respiratory infections (ARI), has today revealed the successful conclusion of IND-enabling studies for its respiratory...

EMA Panel Approves Bavarian Nordic's Vimkunya for Chikungunya Prevention

Bavarian Nordic A/S, a worldwide vaccine firm dedicated to enhancing health and saving lives via innovative vaccines, revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a...

Onco-Innovations Unveils PNKP Inhibitors to Enhance Cancer Treatment Efficacy

Onco-Innovations Limited, a Canadian firm focused on cancer research and treatment, specializing in oncology, has shared details about its licensed technology involving a novel class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors...

Telix Pharma Concludes Acquisition of Antibody Engineering Firm ImaginAb

Telix Pharmaceuticals Limited, a biopharmaceutical firm dedicated to the advancement and marketing of therapeutic and diagnostic radiopharmaceuticals alongside related medical technologies, declared that it has finalized the acquisition from the...

Sudarshan Pharma Secures 188 Cr via 4.3 Cr Convertible Warrants

Sudarshan Pharma Industries revealed the authorization of Rs 188 Cr in capital raising via 4.3 Cr convertible warrants. The firm acknowledged the contract established between the Monitoring agency and the enterprise on January 29, 2025, and...

Union Budget 2025: Healthcare Gets 9.78% Boost, Allocation Nears 1 Lakh Crore

The Union Budget 2025 has proposed a 9.78 per cent rise in funding for healthcare for the fiscal year 2025-26, amounting to Rs. 99,858.56 crore in contrast to Rs. The ministry of health and family welfare states that the amount will be 90,958.63...

Renalys Pharma Concludes Patient Enrollment for Phase III Trial

Renalys Pharma, Inc., a privately owned late-stage clinical biopharmaceutical firm located in Japan, declared that it has finalized patient enrollment and achieved the target case number for its registrational phase III clinical trial of...

March Bioscience's MB-105 CAR-T Therapy Earns FDA Orphan Drug Status

Houston-based March Biosciences, an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, announced that the US Food and Drug Administration (FDA) granted orphan drug designation to MB-105...

Quantum-Si & IDEX Health Partner to Advance Proteus Proteomics Platform

Quantum-Si Incorporated, the protein sequencing firm, and IDEX Health & Science, LLC, announced a collaboration to develop and manufacture the optics module for Quantum-Si's innovative proteomics platform, Proteus. IDEX Health & Science, LLC...

© 2025 India Pharma Outlook. All Rights Reserved.